Advanced Filters
noise

Bethesda, Maryland Clinical Trials

A listing of Bethesda, Maryland clinical trials actively recruiting patient volunteers.

Found 1,597 clinical trials
E Elahe Mollapour

Early Screening and Treatment of Heart Complication in Sickle Cell Disease

This study tests whether early heart screening and treatment for iron overload in subjects with sickle cell disease can prevent heart problems and reduce hospitalizations.

18 years of age All Phase 2
V Vanessa B Sheppard, PhD

CONTIGO - A Narrative Intervention to Enhance Genetic Counseling and Testing

This is a mixed-methods Hybrid Type 1 research design (efficacy study) in which we aim to conduct a two-arm randomized controlled trial and an Implementation Focused Process Evaluation of a culturally-targeted video and referral screening tool. In this study, the investigators aim to evaluate the efficacy of a culturally targeted …

18 years of age Female Phase N/A
T Taylor Stephenson

Enzalutamide Implants (Enolen) in Patients With Prostate Cancer

The study is to assess whether the Enolen is safe and delivers anti-androgen medication locally in patients that are planning for radical prostatectomy.

21 years of age Male Phase 1
N Narayan Rai, MD

Development and Evaluation of Computerized Chemosensory-Based Orbitofrontal Networks Training for Treatment of Pain (CBOT-P)

The overarching goal of this study phase, Phase II component is to perform a randomized clinical trial of the refined Computerized Chemosensory-Based Orbitofrontal Networks Training for Treatment of Pain \[CBOT-Pain (or CBOT-P)\] from Phase I, compared to sham Computerized Chemosensory-Based Orbitofrontal Networks Training (CBOT) in Chronic Low Back Pain (CLBP) …

18 - 85 years of age All Phase 2
J James C West, MD

Nightmare Deconstruction and Reprocessing vs. NightWare Wristband

The overall goal of this Phase IIa randomized controlled pilot trial is to assess the potential efficacy of two emerging treatments for post-trauma nightmares and to test the feasibility of study design and methods. Symptom change will be assessed in two treatment arms: (1) Nightmare Deconstruction and Reprocessing (NDR), an …

22 - 64 years of age All Phase 2
F For more information at the NIH Clinical Center contact Office of Patient Recruitment (OPR)

Modeling Host-Pathogen Interaction Using Lymphoid Organoids

Background Staphylococcus aureus (S.aureus) are bacteria that can make people sick. Sometimes, an S. aureus infection can develop inside the spine; these infections can lead to paralysis and death. Researchers do not know how S. aureus interacts with a person s cells to cause infections in the spine. Objective To …

2 - 120 years of age All Phase N/A
V Valerie Darcey

Diet Order Effects of Low Fat vs. Low Carb Diets on Body Fat Change

Background In a previous study, participants were lived at the NIH and randomly received either a low-fat or a low-carbohydrate diet for 2 weeks and then switched to the other diet for 2 more weeks. Participants who received the low-carbohydrate diet first lost more body fat at the end of …

18 - 50 years of age All Phase N/A
N National Cancer Institute Referral Office

18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection

Background Fibroblast-activation protein (FAP) is an enzyme that appears in high numbers in cancer-associated fibroblasts of certain cancer types. \[18F\]FAPI-74 is a new PET (positron emission tomography) tracer, a substance that is injected into a person s body before an imaging scan. Researchers believe that \[18F\]FAPI-74 PET imaging may be …

18 - 120 years of age All Phase 2
N National Cancer Institute Referral Office

A UGT1A1 Genotype-Directed Study of Belinostat Pharmacokinetics and Toxicity

Background High-grade neuroendocrine carcinomas (HGNEC) are cancers that develop in different parts of the body, including the digestive tract, genitals, neck, and head. One drug (belinostat), combined with 2 other drugs (etoposide and cisplatin), is approved to treat HGNEC. But some people may have a gene variant that affects how …

18 - 120 years of age All Phase 2
C Carl E. Allen, MD, PhD

Study of the ITK Inhibitor Soquelitinib to Reduce Lymphoproliferation and Improve Cytopenias in Autoimmune Lymphoproliferative Syndrome (ALPS)-FAS Patients

Background Autoimmune lymphoproliferative syndrome (ALPS) is a rare disorder of the immune system caused by a mutation in the FAS gene. In ALPS, the body stores too many germ-fighting cells called lymphocytes. This can lead to an enlarged spleen and lymph nodes. Current treatments for ALPS can have many adverse …

16 - 120 years of age All Phase 2

Simplify language using AI